中国卫生标准管理
中國衛生標準管理
중국위생표준관리
CHINA HEALTH STANDARD MANAGEMENT
2015年
2期
65-66
,共2页
索拉非尼%晚期肾癌%近远期效
索拉非尼%晚期腎癌%近遠期效
색랍비니%만기신암%근원기효
Sola Fini%Advanced renal cel carcinoma%Short and long term effect
目的：对索拉非尼在晚期肾癌患者临床治疗中的近远期效果分析。方法在我院2008年8月～2009年8月实施治疗的晚期肾癌中选取80例，分成两组，对比分析两组患者的临床治疗效果。结果对照组和观察组患者的临床治疗有效率分别为57.5%、80.0%，差异显著（P<0.05）；观察组患者的临床不良反应率明显低于对照组，差异显著（P<0.05）；和对照组相比，观察组患者的治疗远期也具有明显优势，差异显著（P<0.05）。结论在晚期肾癌患者临床治疗中加上索拉非尼能够显著改善患者的治疗近远期效果，值得推广应用。
目的：對索拉非尼在晚期腎癌患者臨床治療中的近遠期效果分析。方法在我院2008年8月～2009年8月實施治療的晚期腎癌中選取80例，分成兩組，對比分析兩組患者的臨床治療效果。結果對照組和觀察組患者的臨床治療有效率分彆為57.5%、80.0%，差異顯著（P<0.05）；觀察組患者的臨床不良反應率明顯低于對照組，差異顯著（P<0.05）；和對照組相比，觀察組患者的治療遠期也具有明顯優勢，差異顯著（P<0.05）。結論在晚期腎癌患者臨床治療中加上索拉非尼能夠顯著改善患者的治療近遠期效果，值得推廣應用。
목적：대색랍비니재만기신암환자림상치료중적근원기효과분석。방법재아원2008년8월～2009년8월실시치료적만기신암중선취80례，분성량조，대비분석량조환자적림상치료효과。결과대조조화관찰조환자적림상치료유효솔분별위57.5%、80.0%，차이현저（P<0.05）；관찰조환자적림상불량반응솔명현저우대조조，차이현저（P<0.05）；화대조조상비，관찰조환자적치료원기야구유명현우세，차이현저（P<0.05）。결론재만기신암환자림상치료중가상색랍비니능구현저개선환자적치료근원기효과，치득추엄응용。
Objective The short and long term effects of sorafenib in advanced kidney cancer patients in clinical therapy.Methods In our hospital in August 2008 to implement the treatment in August 2009 selected 80 cases of advanced kidney cancer, divided into two groups, comparative analysis of the two groups of patients with clinical treatment. ResultsThe clinical treatment control group and observation group were effective were 57.5%, 80.0%,were significantly different(P<0.05); Clinical adverse reaction rates observed in patients was significantly lower than the control group, the difference was significant (P<0.05);Compared to the control group, the treatment of patients with long-term observation group also has obvious advantages, significant difference (P<0.05).ConclusionIn the clinical treatment of patients with advanced renal cel carcinoma plus sorafenib therapy can significantly improve the short and long term effects of the patient, should be widely applied.
